Neptune Medical Wins FDA 510(k) Clearance for Triton 1 Robotic Colonoscopy System

Colorectal cancer is the second leading cause of cancer death in the United States, and it is increasingly affecting adults under the age of 50. For decades, colonoscopy has been the gold standard for screening because it is the only procedure that allows doctors to both detect and remove precancerous lesions in a single session. Yet the procedure remains technically demanding. Even highly trained gastroenterologists can struggle to control today's endoscopes, and instability can limit visualization, contribute to missed adenomas and increase clinician strain. That combination of clinical importance and technical difficulty has made colonoscopy a prime target for robotic assistance.

On September 16, 2026, Neptune Medical, a venture-backed medical device company headquartered in Burlingame, California, announced that the U.S. Food and Drug Administration had granted 510(k) clearance to its Triton 1 System. The company described the product as a robotic platform purpose-built for next-generation flexible endoscopy and indicated for diagnostic and therapeutic procedures throughout the colon. The clearance covers screening, surveillance and diagnostic colonoscopies as well as more complex procedures such as endoscopic mucosal resections (EMRs) and endoscopic submucosal dissections (ESDs).

The FDA decision follows a first-in-human clinical study called CARE 1, which Neptune Medical presented earlier this year at Digestive Disease Week 2026. The trial enrolled 50 adults at a single center in Poland who underwent screening, surveillance or diagnostic colonoscopy with the Triton system and were followed for 14 days after the procedure. According to the company, the study met both of its primary endpoints, with no adverse events and 100% cecal intubation, meaning the robot successfully reached the deepest part of the colon in every case.

Neptune Medical is not a newcomer to the endoscopy space. The company builds on a proprietary Dynamic Rigidization platform technology and raised $97 million in Series D funding in 2024. Its founder and CEO, Alex Tilson, has argued that robotics can change the fundamental experience of colonoscopy for both physicians and patients. The FDA clearance now gives the company a regulatory green light to bring that vision to the U.S. market.

Key Facts

The Robot Report reported on September 18 that Neptune Medical won FDA clearance for the Triton 1 System, calling it a GI robotic endoscopy platform that reached 100% cecal intubation and a 54.2% adenoma detection rate in its first-in-human trial.

CancerNetwork reported on September 17 that the FDA granted 510(k) clearance to the Triton 1 Robotic Endoscopy System for diagnostic and therapeutic procedures throughout the colon. The publication detailed the CARE 1 study (NCT06935734) of 50 adults who underwent screening, surveillance or diagnostic colonoscopy with the Triton system at a single center in Poland and were followed for 14 days after the procedure. It met both primary endpoints, with no adverse events and 100% cecal intubation. The system also demonstrated an adenoma detection rate of 54.2%, a polyp detection rate of 67.5% and 100% polypectomy success.

MPO reported on September 17 that Neptune Medical received FDA clearance for Triton 1, a robotic system for flexible endoscopy throughout the colon, citing a 54.2% adenoma detection rate and 67% lower endoscopist workload. The magazine explained that today's endoscopes can be difficult to control, even for highly trained gastroenterologists, and that instability can limit visualization, contribute to missed adenomas and increase clinician strain.

BioSpace reported on September 16 that Neptune Medical announced FDA clearance for its Triton 1 System. The release stated that the robot is designed to deliver robotic precision, stability and control throughout the entire colon. It also highlighted the CARE 1 results: no adverse events, 100% cecal intubation, a 54.2% adenoma detection rate compared to the industry threshold of 35%, and a 67% lower average endoscopist burden versus manual colonoscopy based on the NASA Task Load Index. Investigators reported no patient repositioning, abdominal pressure or conversion to manual colonoscopy.

Alex Tilson, founder and CEO of Neptune Medical, said in the release that 'Triton has the potential to fundamentally transform colonoscopy... Achieving regulatory clearance in the U.S. brings us one step closer to that reality.' He added that the company is using this generation of the Triton system to build on the evidence from its recent trial and to learn from endoscopists how robotics should integrate into their workflow, insights that will directly shape its next-generation platform. Jason B. Samarasena, MD, chief of the Division of Gastroenterology and Hepatology at the University of California, Irvine, and an investigator on CARE 1, said that bringing robotics to lower GI procedures is an exciting prospect and that Triton 'showed us the possibility of one system that can screen and treat anywhere in the colon, efficiently, thoroughly, and with minimal burden.'

Analysis

What this really means is that robotic endoscopy is moving from concept to cleared clinical product in the United States. The Triton 1 clearance is not simply another 510(k) for a niche device. It signals that the FDA has accepted a robotic platform for use throughout the colon, including advanced interventions such as EMR and ESD, based on a 50-patient first-in-human study. That is a notable regulatory milestone for a field where manual colonoscopy has dominated for decades.

The CARE 1 data help explain why regulators and clinicians are paying attention. A 54.2% adenoma detection rate is well above the 35% industry threshold, and a 67.5% polyp detection rate with 100% polypectomy success suggests the system can support both finding and removing lesions. The 67% reduction in average endoscopist burden on the NASA Task Load Index is equally significant. Colonoscopy is physically and mentally demanding, and anything that reduces strain without compromising thoroughness could improve the sustainability of screening programs.

The bigger picture here is that Neptune Medical is betting on a workflow shift, not just a technology upgrade. Tilson's comment about learning from endoscopists how robotics should integrate into their workflow suggests the company understands that adoption depends on more than regulatory clearance. The CARE 1 study was conducted at a single center in Poland, which is an important limitation. A 50-patient trial with 14-day follow-up cannot capture rare complications, long-term outcomes or performance across diverse patient populations and operator skill levels. The FDA clearance allows marketing, but broader clinical and economic evidence will determine how quickly the system spreads.

It is also worth noting that Neptune Medical raised $97 million in Series D funding in 2024, which gives it resources to support a commercial launch. The company is venture-backed and headquartered in Silicon Valley, and it has built its robot on a proprietary Dynamic Rigidization platform technology. That platform foundation could allow future iterations to address other parts of the gastrointestinal tract, although no such indications are cleared today. For now, the cleared indication is specific: diagnostic and therapeutic procedures anywhere in the colon.

Why It Matters

Colorectal cancer is the second leading cause of cancer death in the United States, and it is increasingly affecting adults under age 50. Screening is critical because colonoscopy is the only procedure that allows both detection and removal of precancerous lesions in one session. If a robotic system can make that procedure more consistent, less burdensome for clinicians and more effective at finding adenomas, the public health implications could be substantial.

The endoscopist burden finding also matters in a practical sense. Gastroenterology faces workforce pressures, and procedures that are physically taxing can contribute to burnout and early retirement. A 67% lower average burden on the NASA Task Load Index, if confirmed in broader use, could help extend careers and make high-quality colonoscopy more sustainable. The fact that the system achieved 100% cecal intubation without patient repositioning or abdominal pressure also points to a potentially more standardized procedure, which could reduce variability between operators.

Still, clearance is not the same as adoption. Payers, hospitals and clinicians will want to see real-world data on cost-effectiveness, procedure times and patient outcomes. The CARE 1 study was small and conducted outside the United States, so U.S. gastroenterologists will likely want additional evidence before changing their practice. Neptune Medical's next steps, including how it trains endoscopists and integrates the robot into existing workflows, will be closely watched.

Next Up

Neptune Medical has said it is using this generation of the Triton system to build on the evidence from its recent trial and to learn from endoscopists how robotics should integrate into their workflow, insights that will directly shape its next-generation platform. That suggests the company views the current clearance as a foundation rather than a finished product.

In the near term, the company will need to support clinical adoption in the U.S. market. No additional trials or launch timelines were disclosed in the materials reviewed. The key question is whether the strong first-in-human results can be reproduced in larger, more diverse settings, and whether hospitals see enough value to invest in a new robotic platform for colonoscopy.